Tefibazumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Tefibazumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetClumping factor A
Clinical data
Trade namesAurexis
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6548H10122N1730O2034S44
Molar mass147.590 kg/mol g·mol−1
 ☒N☑Y (what is this?)  (verify)

Tefibazumab (named Aurexis but not approved) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in a phase 2a patients with cystic fibrosis[1] and of methicillin-resistant S. aureus.[2]

It was developed by Inhibitex.[3]

See also[edit]

  • MSCRAMM (microbial surface components recognizing adhesive matrix molecules)

References[edit]

  1. ^ Clinical trial number NCT00198289 at ClinicalTrials.gov
  2. ^ Pan; Lorenzotti, S.; Zoncada, A. (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent Patents on Anti-infective Drug Discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183.
  3. ^ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.